[
    {
        "outcome_uid": "c332fbab",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "Abatacept",
        "outcome": "Remission (follow up: 1 year; assessed with: DAS28 - CRP < 2.6)",
        "importance": "CRITICAL",
        "related_paper_list": [
            "2a7a858b"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "ABA": "48/113 (42.5%)",
                    "MTX monotherapy": "52/115 (45.2%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "RR 0.94 (0.70 to 1.26)",
                    "Absolute Effect (95% CI)": "27 fewer per 1,000 (from 136 fewer to 118 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "4aebaaf2",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "Abatacept",
        "outcome": "Disability (follow up: 1 year; assessed with: HAQ - DI \u2265 0.3)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "2a7a858b"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "ABA": "61/113 (54.0%)",
                    "MTX monotherapy": "51/115 (44.3%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.22 (0.93 to 1.59)",
                    "Absolute Effect (95% CI)": "98 more per 1,000 (from 31 fewer to 262 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "25ad7b5e",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "Abatacept",
        "outcome": "Serious adverse events (1 year)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "2a7a858b"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "ABA": "14/116 (12.1%)",
                    "MTX monotherapy": "9/116 (7.8%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.56 (0.70 to 3.45)",
                    "Absolute Effect (95% CI)": "43 more per 1,000 (from 23 fewer to 190 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "a6610de9",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "Abatacept",
        "outcome": "Withdrawal due to adverse events (follow up: 1 year)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "2a7a858b"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "ABA": "8/116 (6.9%)",
                    "MTX monotherapy": "5/116 (4.3%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "RR 1.60 (0.54 to 4.75)",
                    "Absolute Effect (95% CI)": "26 more per 1,000 (from 20 fewer to 162 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "e24b57d2",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "Abatacept",
        "outcome": "Withdrawal due to lack of efficacy (follow up: 1 year)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "2a7a858b"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Confidence interval includes both values suggesting benefit and values suggesting harm. Small sample size."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "ABA": "6/116 (5.2%)",
                    "MTX monotherapy": "11/116 (9.5%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "RR 0.55 (0.21 to 1.43)",
                    "Absolute Effect (95% CI)": "43 fewer per 1,000 (from 75 fewer to 41 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "614a8019",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "Abatacept",
        "outcome": "Death (follow up: 1 year)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "2a7a858b"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Small sample size and very low number of events."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "ABA": "0/116 (0.0%)",
                    "MTX monotherapy": "0/116 (0.0%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "not estimable",
                    "Absolute Effect (95% CI)": "",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "0957c585",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "Abatacept",
        "outcome": "Malignancy (follow up: 1 year)",
        "importance": "IMPORTANT",
        "related_paper_list": [
            "2a7a858b"
        ],
        "assessment_results": {
            "GRADE": {
                "Risk of bias": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Inconsistency": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Indirectness": {
                    "result": "NOT_SERIOUS",
                    "rationales": ""
                },
                "Imprecision": {
                    "result": "VERY_SERIOUS",
                    "rationales": "Downgraded by two levels due to very serious imprecision. Small sample size and very low number of events."
                },
                "Other considerations": {
                    "result": "none",
                    "rationales": ""
                },
                "Study design": "Randomized Controlled Trial",
                "Certainty": "LOW",
                "No of participants": {
                    "ABA": "2/116 (1.7%)",
                    "MTX monotherapy": "1/116 (0.9%)"
                },
                "Annotation": {},
                "Effect": {
                    "Relative Effect (95% CI)": "RR 2.00 (0.18 to 21.75)",
                    "Absolute Effect (95% CI)": "9 more per 1,000 (from 7 fewer to 179 more)",
                    "Abbreviations": "CI: Confidence interval; RR: Risk ratio; MD: Mean difference; HR: Hazard Ratio"
                }
            }
        }
    },
    {
        "outcome_uid": "3f5df505",
        "clinical_question": "Should patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity receive MTX monotherapy or boDMARD monotherapy or tsDMARD monotherapy?",
        "population": "Patients with MTX-na\u00efve and non-MTX csDMARDs na\u00efve RA and moderate to high disease activity",
        "intervention": "MTX monotherapy",
        "comparator": "Abatacept",
        "outcome": "Malignancy (from SR of harms) ABA vs MTX",
        "related_paper_list": [
            "1fbf0f4e"
        ],
        "assessment_results": {
            "GRADE": {
                "result_interpretation": "The Systematic Review RefID=1220, 2017 (RCTs=4, n=Not provided) comparing Abatacept vs Placebo + csDMARD among RA and showed that for Cancer, the result was Peto OR=1.12 (0.33, 3.81)",
                "Study design": "Systematic Review"
            }
        }
    }
]